title: Adverse reactions in patients with B-cell lymphomas during combined treatment with rituximab: In vitro evaluation of rituximab hypersensitivity by basophil activation test.
authors.forename: Elisa
authors.initials: E
authors.lastname: Piva
authors.forename: Fulvia
authors.initials: F
authors.lastname: Chieco-Bianchi
authors.forename: Valentino
authors.initials: V
authors.lastname: Krajcar
authors.forename: Savina
authors.initials: S
authors.lastname: Aversa
authors.forename: Mario
authors.initials: M
authors.lastname: Plebani
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001491:Basophils / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000209:etiology* / Q000276:immunology; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D060149:Tetraspanin 30 / Q000276:immunology
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C554586:CD63 protein, human; D060149:Tetraspanin 30; D000069283:Rituximab